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Abstract
Aims Health insurance claims (HIC) databases in the Netherlands capture unselected patient populations, which makes them
suitable for epidemiological research on sex differences. Based on a HIC database, we aimed to reveal sex differences in heart
failure (HF) outcomes, with particular focus on co‐morbidities and medication.
Methods and results The Achmea HIC database included 14 517 men and 11 259 (45%) women with a diagnosis treatment
code for chronic HF by January 2015. We related their sex, co‐morbidities, and medication adherence (medication possession
rate >0.8) with the primary endpoint (PE) of all‐cause mortality or HF admission during a median follow‐up of 3.3 years, using
Cox regression. Median age of men and women was 72 and 76 years, respectively. Prevalence of co‐morbidities and use of
disease‐modifying drugs was higher in men; however, medication adherence was similar. At the end of follow‐up, 35.1%
men and 31.8% women had reached the PE. The adjusted hazard ratio for men was 1.25 (95% confidence interval:
1.19–1.30). A broad range of co‐morbidities was associated with the PE. Overall, these associations were stronger in women
than in men, particularly for renal insufficiency, chronic obstructive pulmonary disease/asthma, and diabetes. Non‐adherence
to disease‐modifying drugs was related with a higher incidence of the PE, with similar effects between sexes.
Conclusions In a representative sample of the Dutch population, as captured in a HIC database, men with chronic HF had a
25% higher incidence of death or HF admission than women. The impact of co‐morbidities on the outcome was sex depen-
dent, while medication adherence was not.
Keywords Heart failure; Co‐morbidity; Medication adherence; Hospitalisation; Mortality; Big data
Received: 26 May 2020; Revised: 26 September 2020; Accepted: 29 October 2020
*Correspondence to: Professor Eric Boersma, MSc, PhD, FESC, Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam, Doctor
Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Tel: (010) 703-1814. Email: h.boersma@erasmusmc.nl
Introduction
Randomized controlled trials (RCTs) are broadly accepted as
the golden standard to evaluate the efficacy and safety of
pharmacological treatment. However, RCTs usually have
strict inclusion and exclusion criteria, which makes their
representativeness for clinical practice questionable. For
example, in the cardiovascular domain, including heart failure
(HF), RCT participants are selected from a predominantly
(younger) male patient population,1 whereas (elderly)
women and those with more complex diseases are often
underrepresented.2 Hence, RCTs insufficiently cover the het-
erogeneity of the HF population, including the broad variety
of socio‐economic factors, the presence of (multiple) co‐mor-
bidities, and medication adherence among men and women.
Consequently, clinical trial databases are generally less suit-
able for studying any sex‐specific effect of these factors on
HF outcomes.
In the Netherlands, over 99% of the population has (basic)
health insurance3 as such insurance is mandatory by law.
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Thus, health insurance claims (HIC) databases in the
Netherlands capture truly representative (random) samples
of patient populations. The sample sizes are large, and data
on co‐morbidities and medication claims are collected in a
systematic way.4 We used the HIC database of Zilveren Kruis
Achmea, one of several health insurance companies, to
describe the key characteristics of an unselected population
of men and women with chronic heart failure (CHF) and to
study the sex‐specific impact of co‐morbidities and medica-
tion on prognosis.
Methods
Study design and patient selection
A retrospective, observational study was carried out using
anonymous HIC data of Zilveren Kruis Achmea, the largest in-
surance company in the Netherlands comprising about 5.1
million people (30%) of the Dutch population.5 The database
contained data from January 2012 to April 2018. The period
until December 2014 was used for patient selection and de-
termining characteristics of the study sample. Between Janu-
ary 2015 and April 2018, the outcomes of the selected
patients were determined.
We identified 25 776 patients aged 18–85 years with a di-
agnosis treatment code for CHF and still alive by January 2015
(Figure 1). These patients had a CHF‐related claim according
to the national diagnosis treatment classification system
called ‘Diagnose Behandeling Combinatie’ (DBC), which is a
combination of the International Classification of Diseases,
10th revision (ICD‐10)6 and treatment applied. Additionally,
they had used at least one prescription drug within the car-
diovascular system (‘C’) based on World Health Organization
Anatomical Therapeutic Chemical Classification index and
Defined Daily Dose (WHO ATC/DDD) in the same period.7
According to the European Society of Cardiology Heart Fail-
ure guidelines,8 CHF patients should visit their treating physi-
cian at least once per year. To improve data quality, we
therefore excluded patients who lacked any HF insurance
claims after January 2015. Patients who switched to another
insurance company between 2012 and 2018 were also
excluded.
Co‐morbidity selection
Co‐morbidities were identified using a combination of the
adapted diagnosis‐related group (DRG) classification and the
pharmacy‐based cost group (FKG classification). In the
Netherlands, DRG is an ICD‐10‐based system, used to
determine health care costs in relation to specific diseases.
The FKG is a classification method for medication type/dose
in relation to chronic diseases, which is used in the national
risk equalization model. It is used to adjust capitation
Figure 1 Flowchart of study population selection.
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payments by the health care insurer to the health care
provider.
Medication use and adherence
Medication use and adherence was determined for the
period 2012–2014. Extensive pharmacy data were available.
The indication for prescribing a certain drug of selection is
not known. Medication adherence was determined using
the medication possession ratio (MPR).9 This ratio was de-
fined as the amount of pills corrected for different dosage
schemes, the prescribed daily dose supplied, divided by the
time (days) between two supply dates. Patients may switch
drugs within the same class. Therefore, to obtain more
reliable MPR estimates, medications were grouped into ATC
classes. Consecutively, MPR was averaged over the total
supply period per ATC group and categorized based on a
threshold of 0.80, above which a patient was considered ad-
herent to prescribed medication.9
Outcomes and follow‐up
The primary endpoint (PE) was a composite of all‐cause mor-
tality and hospitalisation for HF, based on the DBC system.
Secondary endpoints were the two components of this com-
posite. Biological sex differences in co‐morbidities and medi-
cation adherence in relation to the PE were of particular
interest. Mortality was retrieved from the civil registry. HF ad-
missions were not adjudicated by a committee.
For additional information on patient selection, definition
of socio‐demographic factors, co‐morbidities, medication ad-
herence, and outcomes, see Supporting Information,
Appendix S1.
Statistical analysis
Continuous variables are presented as median and interquar-
tile range, and sex differences were evaluated using Mann–
Whitney tests. Categorical variables are presented as counts
and percentages, and sex differences were evaluated using
χ2‐tests.
The associations between sex, co‐morbidities, and medica-
tion adherence and the PE were assessed using Cox propor-
tional hazard regression models, with adjustment for other
predefined, clinically relevant baseline variables, including
age, marital status, socio‐economic status, income level,
and time since last CHF‐related outpatient/clinic visit. The
proportional hazard assumption was satisfied for each vari-
able. We investigated potential effect modification by sex
via an interaction term in the Cox models.
For all tests, a P‐value < 0.05 was considered statistically
significant. Data were analysed using R Statistical Software
Version 3.4.2 (Vienna, Austria) and the "survival" package.
Results
Baseline characteristics and co‐morbidities
The analysis set included 14 517 (55%) men and 11 259 (45%)
women. Women were significantly older (76 vs. 72 years).
Baseline characteristics are described in Table 1. More than
a third of the patients (35%) had three or more co‐morbid-
ities. Arrhythmia (41%), ischaemic heart disease (33%), diabe-
tes mellitus type 1 or 2 (DM1/2) (25%), malignancy (25%),
and chronic obstructive pulmonary disease (COPD)/asthma
(17%) were most common. Men had a higher prevalence of
these top five co‐morbidities. Women had a higher preva-
lence of valvular heart disease, hypertensive disease, thyroid
dysfunction, and depression. Men and women had a similar
prevalence of renal insufficiency (RI) and cerebrovascular
disease.
Medication use and adherence
Baseline medication use is shown in Table 2. The vast major-
ity of patients used angiotensin‐converting enzyme‐inhibi-
tors/angiotensin receptor blockers (ACE‐I/ARBs) (85%),
beta‐blockers (83%), or diuretics (83%), in particular loop
diuretics (71%) and mineralocorticoid receptor antagonists
(MRAs) (40%). Up to a third used calcium blockers (33%),
and digoxin was prescribed in 19% of patients. Almost a quar-
ter of patients (23%) used oral nitrates (isosorbide). Cardio-
vascular medication use, in particular disease‐modifying
drugs, was somewhat higher in men, except for calcium
blockers, diuretics, and digoxin.
Baseline medication adherence based on MPR is pre-
sented in Table 3. The adherence was largely similar in
men and women in each ATC group. A (borderline) statisti-
cally significant difference between both sexes was ob-
served for ACE‐I/ARBs, beta‐blockers, loop diuretics, and
MRAs.
Outcomes
Median follow‐up time was 3.3 years (interquartile range
2.2–3.3). The PE of all‐cause mortality or HF hospitalisation
was reached in 8669 patients (34%) (Table 4). A total of
7152 patients (28%) died, and 3179 (12%) were hospital-
ized. Men had a higher incidence of the PE than women
(35.1% vs. 31.8%). Adjusted hazard ratio (aHR) for the com-
posite endpoint was 1.25 (95% confidence interval:
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Table 1 Baseline characteristics
Characteristics All patients N = 25 776 Men N = 14 517 Women N = 11 259 P‐value
Age (years), median (IQR) 74 (66–80) 72 (65–79) 76 (67–81) <0.001
Sex, n (%)
Men 14 517 (56)
Women 11 259 (44)
Marital status, n (%) <0.001
Married 8697 (34) 6007 (41) 2690 (24)
Unknown 8428 (33) 4616 (32) 3812 (34)
Widow/widower 3802 (15) 1211 (8) 2591 (23)
Never married 3040 (12) 1823 (13) 1217 (11)
Divorced 1809 (7) 860 (6) 949 (8)
SES score, median (IQR) 0.37 (1.17 to 0.47) 0.15 (1.17 to 0.35) 0.21 (1.26 to 0.40) <0.001
Income level, median (IQR) 5.0 (2.0–7.0) 5.0 (2.0–7.0) 5.0 (2.0–7.0) <0.001
Duration since last visita, n (%) <0.001
0–6 months 2993 (12) 1617 (11) 1376 (12)
6–12 months 3327 (13) 1822 (13) 1505 (13)
1–2 years 6975 (27) 3827 (26) 3148 (28)
>2 years 12 481 (48) 7251 (50) 5230 (46)
Co‐morbiditiesb, n (%) <0.001
0 2614 (10) 1363 (9) 1251 (11)
1 6552 (25) 3562 (25) 2990 (27)
2 7604 (30) 4419 (30) 3185 (28)
≥3 9006 (35) 5173 (35) 3833 (34)
History of co‐morbiditiesb, n (%)
Arrhythmia 10 569 (41) 6409 (44) 4160 (37) <0.001
Ischaemic heart disease 8445 (33) 5045 (35) 3400 (30) <0.001
Diabetes mellitus 1/2 6500 (25) 3789 (26) 2711 (24) <0.001
Malignancy 6328 (25) 3703 (26) 2625 (23) <0.001
COPD/asthma 4433 (17) 2609 (18) 1824 (16) <0.001
Hypercholesterolaemia 3753 (15) 2410 (17) 1343 (12) <0.001
Valve disease 3607 (14) 1864 (13) 1743 (15) <0.001
Renal insufficiency 3110 (12) 1757 (12) 1353 (12) 0.833
Hypertensive disease 2128 (8) 1030 (7) 1098 (10) <0.001
Cerebrovascular disease 1941 (8) 1100 (8) 841 (7) 0.745
Thyroid dysfunction 1792 (7) 595 (4) 1197 (11) <0.001
Depression 1420 (6) 570 (4) 850 (8) <0.001
COPD, chronic obstructive pulmonary disease; IQR, interquartile range; SES, socio‐economic status.
Significant P‐values are in bold.
aDuration since last chronic heart failure outpatient clinic visit or admission in period 2012–2014.
bOnly pre‐selected clinically relevant co‐morbidities.
Table 2 Medication use
All patients N = 25 776 Men N = 14 517 Women N = 11 259 P‐value
Medicationa, n (%)
ACE‐inhibitors/ARBs 21 846 (85) 12 623 (87) 9223 (82) <0.001
Beta‐blockers 21 397 (83) 12 267 (85) 9130 (81) <0.001
Calcium blockers 8446 (33) 4522 (31) 3924 (35) <0.001
Diuretics 21 292 (83) 11 654 (80) 9638 (86) <0.001
Loop diuretics 18 286 (71) 10 056 (69) 8230 (73) <0.001
Thiazide diuretics 6685 (26) 3220 (22) 3465 (31) <0.001
Mineralocorticoid receptor antagonists 10 434 (40) 5956 (41) 4478 (40) 0.042
Digoxin 4980 (19) 2723 (19) 2257 (20) 0.009
Amiodarone 2304 (9) 1524 (10) 780 (7) <0.001
Doxazosin 963 (4) 513 (4) 450 (4) 0.052
Ivabradine 636 (2) 389 (3) 247 (2) 0.013
Hydralazine 119 (0) 83 (1) 36 (0) 0.003
Nitrates (isosorbide) 5946 (23) 3493 (24) 2453 (22) <0.001
Anti‐coagulants 14 482 (56) 8493 (59) 5989 (53) <0.001
Anti‐platelets 13 422 (52) 8094 (56) 5328 (47) <0.001
Lipid‐lowering therapy 17 221 (67) 10 452 (72) 6769 (60) <0.001
Glucose‐lowering therapy 7828 (30) 4498 (31) 3330 (30) 0.015
ACE, angiotensin‐converting enzyme; ARBs, angiotensin receptor blockers.
Significant P‐values are in bold.
aMedication use in period 2012–2014.
66 M.T. Gürgöze et al.
ESC Heart Failure 2021; 8: 63–73
DOI: 10.1002/ehf2.13113
Table 3 Medication adherence
ATC group Adherence All patientsa Mena Womena P‐value
ACE‐I/ARBs, n (%) n = 21 846 n = 12 623 n = 9223
Adherent 18 048 (82.6) 10 482 (83.0) 7566 (82.0) 0.010
Non‐adherent 1327 (6.1) 782 (6.2) 545 (5.9)
Unknown 2471 (11.3) 1359 (10.8) 1112 (12.1)
Beta‐blockers, n (%) n = 21 397 n = 12 267 n = 9130
Adherent 17 737 (82.9) 10 158 (82.8) 7579 (83.0) 0.033
Non‐adherent 1214 (5.7) 736 (6.0) 478 (5.2)
Unknown 2446 (11.4) 1373 (11.2) 1073 (11.8)
Calcium blockers, n (%) n = 8446 n = 4522 n = 4924
Adherent 5782 (68.5) 3127 (69.2) 2655 (67.7) 0.258
Non‐adherent 507 (6.0) 273 (6.0) 234 (6.0)
Unknown 2157 (25.5) 1122 (24.8) 1035 (26.4)
Diuretics, n (%) n = 21 292 n = 11 654 n = 9638
Adherent 15 489 (72.7) 8519 (73.1) 6970 (72.3) 0.403
Non‐adherent 1858 (8.7) 996 (8.5) 862 (8.9)
Unknown 3945 (18.5) 2139 (18.4) 1806 (18.7)
Loop diuretics, n (%) n = 18 286 n = 10 056 n = 8230
Adherent 11 966 (65.4) 6653 (66.2) 5313 (64.6) 0.039
Non‐adherent 2200 (12.0) 1207 (12.0) 993 (12.1)
Unknown 4120 (22.5) 2196 (21.8) 1924 (23.4)
Thiazide diuretics, n (%) n = 6685 n = 3220 n = 3465
Adherent 3823 (57.2) 1837 (57.0) 1986 (57.3) 0.751
Non‐adherent 403 (6.0) 188 (5.8) 215 (6.2)
Unknown 2459 (36.8) 1195 (37.1) 1264 (36.5)
MRA, n (%) n = 10 434 n = 5956 n = 4478
Adherent 7357 (70.5) 4242 (71.2) 3115 (69.6) 0.051
Non‐adherent 903 (8.7) 483 (8.1) 420 (9.4)
Unknown 2174 (20.8) 1231 (20.7) 943 (21.1)
Amiodarone, n (%) n = 2304 n = 1524 n = 780
Adherent 1427 (61.9) 963 (63.2) 464 (59.5) 0.197
Non‐adherent 159 (6.9) 99 (6.5) 60 (7.7)
Unknown 718 (31.2) 462 (30.3) 256 (32.8)
Digoxin, n (%) n = 4980 n = 2723 n = 2257
Adherent 3602 (72.3) 1957 (71.9) 1645 (72.9) 0.636
Non‐adherent 199 (4.0) 114 (4.2) 85 (3.8)
Unknown 1179 (23.7) 652 (23.9) 527 (23.3)
Nitrates (isosorbide), n (%) Refill rate n = 5946 n = 3493 n = 2453
Adherent 2977 (50.1) 1712 (49.0) 1265 (51.6) 0.139
Non‐adherent 252 (4.2) 148 (4.2) 104 (4.2)
Unknown 2717 (45.7) 1633 (46.8) 1084 (45.7)
ACE‐I, angiotensin‐converting enzyme inhibitor; ARBs, angiotensin receptor blockers; ATC, anatomical therapeutic chemical classification;
MRA, mineralocorticoid receptor antagonist.
Significant P‐values are in bold.
aOnly patients who used medication within the specific ATC group and in period between 2012 and 2014.
Table 4 Heart failure outcomes
HF outcomes All patients N = 25 776 Men N = 14 517 Women N = 11 259 P‐value
Mortality or HF hospitalisationa, n (%) 8669 (33.6) 5094 (35.1) 3575 (31.8) <0.001
All‐cause mortality, n (%) 7152 (27.7) 4222 (29.1) 2930 (26.0) <0.001
HF hospitalisation, n (%) 3179 (12.3) 1875 (12.9) 1304 (11.6) 0.001
HF hospitalized n = 3179 Men n = 1875 Women n = 1304
All‐cause mortality, n (%) 1662 (52.3) 1003 (53.5) 659 (50.5) 0.101
HF hospital admissionsb, n (%) 5291 3166 2125 <0.001
1 HF‐related admission 2083 (65.5) 1217 (64.9) 866 (66.4)
2 HF‐related admissions 624 (19.6) 373 (19.9) 251 (19.3)
≥3 HF‐related admissions 472 (14.8) 285 (15.2) 187 (14.3)
HF, heart failure.
Significant P‐values are in bold.
aComposite endpoint.
bCumulative frequency of admissions.
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Table 5 Determinants of all‐cause mortality or heart failure admission
Sex‐specific estimates
Characteristics
All patients Men Women
HR (95% CI) HR (95% CI) HR (95% CI) Interaction P‐value
Age, years 1.04 (1.04–1.05)‡ 1.04 (1.04–1.05)‡ 1.04 (1.04–1.05)‡ 0.473
Sex, men 1.25 (1.19–1.30)‡ — — —
Marital status
Married Reference Reference Reference
Unknown 0.83 (0.79–0.88)‡ 0.80 (0.75–0.86)‡ 0.85 (0.78–0.94)‡ 0.315
Widow/widower 0.95 (0.89–1.01) 0.87 (0.79–0.96)† 0.96 (0.87–1.06) 0.153
Never married 1.20 (1.12–1.30)‡ 1.41 (1.29–1.54)‡ 0.90 (0.79–1.03) <0.001
Divorced 1.22 (1.12–1.33)‡ 1.44 (1.28–1.61)‡ 1.02 (0.89–1.16) <0.001
Duration since last visita 0.95 (0.92–0.97)‡ 0.96 (0.93–0.99)* 0.93 (0.89–0.96)‡ 0.135
Socio‐economic status 0.99 (0.97–1.01) 1.01 (0.99–1.04) 0.96 (0.94–0.99)† 0.005
Income level (0–10) 0.97 (0.97–0.98)‡ 0.98 (0.97–0.99)‡ 0.97 (0.95–0.98)‡ 0.091
Co‐morbidities
Arrhythmia 0.96 (0.92–1.00) 0.95 (0.89–1.00)‡ 0.98 (0.92–1.05)‡ 0.400
Cerebrovascular disease 1.29 (1.20–1.39)‡ 1.27 (1.16–1.39)‡ 1.33 (1.19–1.48)‡ 0.564
COPD/asthma 1.46 (1.39–1.54)‡ 1.39 (1.31–1.48)‡ 1.58 (1.47–1.71) 0.011
Depression 1.09 (0.99–1.19) 1.05 (0.92–1.21) 1.11 (0.98–1.25)‡ 0.587
Diabetes mellitus 1/2 1.33 (1.27–1.40)‡ 1.26 (1.19–1.34)‡ 1.44 (1.34–1.55)‡ 0.004
Hypercholesterolaemia 0.78 (0.72–0.85)‡ 0.78 (0.71–0.87)‡ 0.77 (0.67–0.88)‡ 0.834
Hypertensive disease 0.85 (0.78–0.92)‡ 0.83 (0.74–0.94)† 0.86 (0.77–0.97)* 0.695
Ischaemic heart disease 0.90 (0.86–0.95)‡ 0.87 (0.81–0.92)‡ 0.96 (0.90–1.04) 0.022
Malignancy 1.25 (1.19–1.31)‡ 1.22 (1.15–1.30)‡ 1.29 (1.19–1.38)‡ 0.277
Renal insufficiency 1.49 (1.41–1.58)‡ 1.41 (1.31–1.52)‡ 1.61 (1.48–1.75)‡ 0.018
Thyroid dysfunction 1.01 (0.93–1.09) 0.91 (0.79–1.03) 1.07 (0.97–1.19) 0.046
Valve disease 1.05 (0.99–1.11) 0.98 (0.90–1.06) 1.14 (1.05–1.25)† 0.008
Medication use and adherence
ACE‐inhibitor/ARB
Adherent Reference Reference Reference
Non‐adherent 1.17 (1.06–1.29)† 1.20 (1.06–1.35)† 1.13 (0.97–1.31) 0.537
Unknown 1.18 (1.10–1.27)‡ 1.21 (1.10–1.32)‡ 1.14 (1.03–1.27)* 0.426
Never used 1.11 (1.05–1.19)‡ 1.16 (1.07–1.26)‡ 1.06 (0.97–1.16) 0.144
Beta‐blockers
Adherent Reference Reference Reference
Non‐adherent 1.09 (0.98–1.20) 1.17 (1.03–1.33)* 0.97 (0.82–1.14) 0.064
Unknown 0.99 (0.92–1.07) 1.02 (0.93–1.12) 0.94 (0.84–1.06) 0.282
Never used 1.05 (0.99–1.12) 1.07 (0.99–1.16) 1.03 (0.94–1.13) 0.531
Calcium blockers
Adherent Reference Reference Reference
Non‐adherent 0.98 (0.84–1.14) 1.02 (0.83–1.26) 0.92 (0.73–1.16) 0.502
Unknown 1.04 (0.96–1.13) 1.11 (0.99–1.24) 0.96 (0.85–1.08) 0.076
Never used 0.99 (0.94–1.04) 1.06 (0.99–1.14) 0.90 (0.83–0.97)‡ 0.001
Loop diuretics
Adherent Reference Reference Reference
Non‐adherent 1.00 (0.93–1.08) 1.04 (0.94–1.14) 0.95 (0.85–1.06) 0.232
Unknown 1.03 (0.97–1.09) 0.99 (0.91–1.07) 1.08 (0.99–1.18) 0.132
Never used 0.57 (0.53–0.61)‡ 0.57 (0.53–0.62)‡ 0.55 (0.50–0.62)‡ 0.607
Thiazide diuretics
Adherent Reference Reference Reference
Non‐adherent 1.07 (0.88–1.29) 1.21 (0.93–1.58) 0.94 (0.71–1.23) 0.180
Unknown 1.04 (0.95–1.13) 1.01 (0.90–1.15) 1.07 (0.94–1.21) 0.567
Never used 1.05 (0.98–1.12) 1.08 (0.99–1.19) 1.01 (0.92–1.11) 0.319
MRAs
Adherent Reference Reference Reference
Non‐adherent 1.20 (1.09–1.33)‡ 1.16 (1.02–1.33)* 1.26 (1.08–1.46)† 0.455
Unknown 1.00 (0.93–1.08) 1.03 (0.93–1.13) 0.97 (0.86–1.09) 0.432
Never used 0.77 (0.73–0.81)‡ 0.77 (0.72–0.82)‡ 0.76 (0.71–0.82)‡ 0.793
Amiodarone
Adherent Reference Reference Reference
Non‐adherent 1.06 (0.83–1.35) 0.99 (0.73–1.35) 1.18 (0.81–1.71) 0.479
Unknown 0.78 (0.68–0.90)‡ 0.80 (0.67–0.95)* 0.75 (0.59–0.96)* 0.663
Never used 0.75 (0.69–0.81)‡ 0.76 (0.69–0.84)‡ 0.72 (0.62–0.82)‡ 0.495
Digoxin
Adherent Reference Reference Reference
Non‐adherent 1.00 (0.81–1.24) 0.96 (0.71–1.28) 1.06 (0.76–1.48) 0.640
(Continues)
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1.19–1.30, P < 0.001) for men. Furthermore, men had a
higher overall mortality (29% vs. 26%, P < 0.001). Although
men had higher mortality rates overall, no significant differ-
ence in mortality was found between men and women who
had been admitted (54% vs. 51%, P = 0.101). Men were
hospitalized more often for HF (60% of total admission
count) compared with women (P < 0.001). Sixty‐six per
cent had only one HF‐related admission during follow‐up.
Average length of stay was 8.1 days for both men and
women.
Determinants of the primary endpoint
The patient’s age and a broad range of co‐morbidities
seemed to be predictive of the PE (Table 5). RI (aHR
1.49), COPD/asthma (aHR 1.46), DM1/2 (aHR 1.33), cere-
brovascular disease (aHR 1.29), and malignancy (aHR 1.25)
were the most significant determinants of increased risk.
Interestingly, hypercholesterolaemia, hypertensive disease,
and ischaemic heart disease were associated with a re-
duced risk. Non‐adherence to disease‐modifying drugs was
significantly associated with increased risk, in particular
ACE‐I/ARB (aHR 1.17) and MRA (aHR 1.20), but not beta‐
blockers.
The relationship between the co‐morbidities and the PE
was sex dependent. The sum of the regression coefficients
of the co‐morbidities in the multivariable model in women
(1.67) was larger than in men (0.65). In particular, RI,
COPD/asthma, and DM1/2 had a stronger relationship with
the PE in women. We found no significant difference be-




In this analysis, based on a HIC database of >25 000 patients
with CHF, we have shown that overall men demonstrated a
worse prognosis compared with women. A broad range of
co‐morbidities was significantly associated with increased risk
of all‐cause mortality or HF admission. These associations
were somewhat stronger in women than in men, in particular
for RI, COPD/asthma, and diabetes, despite a higher preva-
lence in men. Men used more disease‐modifying drugs; how-
ever, adherence was similar between sexes. Non‐adherence
to disease‐modifying drugs was related with a higher inci-
dence of the PE, which again was similar between sexes.
Several large, national population‐based studies or regis-
tries on HF in Europe with >10 000 (10 190–88 195) patients
have been published.10–14 To our knowledge, in the
Netherlands, only two clinical registries on CHF exist, both
having assessed European Society of Cardiology guideline ad-
herence to HF medication.12,15 The average age of patients
across these large population‐based databases was 72–
78 years, which is similar to our study (74 years). The percent-
age of women was 40–55% compared with 44% in our study,
which is considerably higher than RCTs on HF with a median
of about 29%.16 Considering the gender gap of ~25% be-
tween RCTs and the population at large reported for the US
population,16 one would expect close to 50% female repre-
sentation in a registry or insurance dataset. In the
CHAMP‐HF registry, the average age (66 vs. 74 years) and
percentage of women (29% vs. 44%) were lower compared
with our study. This difference can be explained by the inclu-
sion of solely HF with reduced ejection fraction (HFrEF) out-




All patients Men Women
HR (95% CI) HR (95% CI) HR (95% CI) Interaction P‐value
Unknown 0.91 (0.82–1.01) 0.87 (0.75–0.998)* 0.97 (0.83–1.13) 0.290
Never used 0.89 (0.84–0.94)‡ 0.89 (0.83–0.96)† 0.89 (0.81–0.96)† 0.843
Nitrates (isosorbide)
Adherent Reference Reference Reference
Non‐adherent 1.08 (0.89–1.32) 0.98 (0.76–1.27) 1.25 (0.94–1.68) 0.215
Unknown 0.88 (0.81–0.95)† 0.85 (0.76–0.94)† 0.93 (0.81–1.06) 0.283
Never used 0.80 (0.75–0.85)‡ 0.81 (0.75–0.88)‡ 0.79 (0.72–0.87)‡ 0.619
ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; CI, confidence interval; COPD, chronic obstructive pulmonary
disease; HR, hazard ratio; MRAs, mineralocorticoid receptor antagonists.
Significant interaction P‐values are in bold.
aDuration in years since last chronic heart failure outpatient clinic visit or admission in period between 2012 and 2014.
*Significant at P ≤ 0.05.
†Significant at P ≤ 0.01.
‡Significant at P ≤ 0.001.
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Guidelines‐Heart Failure (GWTG‐HF) registry17 of 79 291 pa-
tients reported an average of 74–75 years and ~50% were
women, which is relatively comparable with our study.
Co‐morbidities
In this discussion, we will focus solely on the most relevant
co‐morbidities with the highest impact on outcomes in
overall and gender survival analysis. Studies on
co‐morbidities have shown that most patients with CHF
have >2 or even >5 co‐morbidities.18 Most patients in this
dataset had ≥3 co‐morbidities, which is in line with the
literature.
Across the previously described population‐based
studies, prevalence of RI was 15–58%, COPD/asthma
15–32%, DM 25–43%, cerebrovascular disease 13–18%,
and malignancy 5–21%.10,11,13,14,17,19 In our study, this
was 12%, 17%, 25%, 8%, and 25%, respectively. The higher
rate for RI, COPD/asthma, and cerebrovascular disease in
other studies is most likely inherent to the inclusion of
mainly patients from outpatient clinics or after hospital dis-
charge and a difference in classification method introducing
some selection. In a cross‐sectional study of 122 630 CHF
patients >65 of age, non‐cardiac co‐morbidities that had
the highest risk for hospitalisations and overall mortality
were COPD/bronchiectasis, renal failure, diabetes, depres-
sion, and other lower respiratory diseases.20 We showed
that COPD, renal failure, and diabetes indeed have a high
impact on these outcomes; however, depression was not
significantly associated in this study. Chronic kidney disease
(CKD) is associated with worse prognosis in patients with
CHF.21 Analysis of the SwedeHF registry also showed a
strong association of CKD with increased HF hospitalisation
and all‐cause mortality.14 Interestingly, despite an extensive
coverage of all cerebrovascular diseases using DRG codes
and in sharp contrast to the registries where usually only
stroke is examined, in this analysis, the prevalence was
lower due to less selection. Malignancy (covering all neo-
plasms), however, was higher in our study as expected.
Malignancy and cardiovascular disease have shared risk fac-
tors and therefore frequently coincide.22 Recently, Meijers
et al. also demonstrated that HF can be considered a risk
factor for incident cancer.23
In contrast to the overall mortality, no significant differ-
ence in mortality was observed between men and women
who had been admitted for HF during follow‐up. We be-
lieve this discrepancy is due to sub‐selection of patients.
Older women with HF with preserved ejection fraction
(HFpEF) might be overrepresented closing the gap between
the two groups. Sex differences exist in characteristics,
aetiology, co‐morbidities, and prognosis. These differences
might be attributed to the HF aetiology, left ventricular
ejection fraction (HFrEF vs. HFpEF), and New York Health
Association classifications, which were not available in this
dataset. Women have a higher incidence of HF at older
age, have more HFpEF, and suffer more from obesity, dia-
betes, and hypertension, while man have a higher inci-
dence at a younger age with more HFrEF due to
ischaemic aetiology.24 Furthermore, women generally live
longer than men. In our study, women with RI, COPD/
asthma, and diabetes had a worse prognosis, even though
prevalence of RI was not significantly different, and
COPD/asthma and diabetes were more common among
men. In contrast, analysis of the SwedeHF registry showed
that women were more likely to have CKD, with no sex dif-
ference on outcomes after adjustment.14 COPD is more
common in men than women and is in line with the work
of Lawson et al., who showed a 15% higher risk of mortal-
ity in women than men.25 Possible explanations are higher
female age, pathophysiology, or delay in or poor response
to treatment. Diabetes was more common among men in
the SwedeHF registry, similar to ours.14 However, the study
of Marra et al. demonstrated that women had more diabe-
tes than men.24 Similar to our study, Johansson et al.
showed that diabetes was a stronger predictor for mortality
in women than men.26 This might be due to less
evidence‐based management in women leading to a poor
control of glucose levels.
Medication use and adherence
Across the large population‐based studies, ACE‐I/ARBs use
was 51–91%, beta‐blockers 52–90%, MRAs 12–56%, and
loop diuretics 53–81%.12–15,17,19 In our study, this was
85%, 83%, 40%, and 83%, respectively. Notably, there is a
considerably large variation across studies, which might be
related to differences in definition. Use of most of the
aforementioned medications was particularly lower in
the US registries, most likely due to lower guideline
adherence.17,19 Prescription rates in our study were compa-
rable with the contemporary Dutch CHECK‐HF registry, a
more clearly defined HF population, although we found
lower rates for MRAs (40% vs. 56%) and loop diuretics
(71% vs. 81%), which can be attributed to focus on HFrEF
patients who are possibly more symptomatic (26%, New
York Health Association III).15
As expected, ACE‐I/ARBs and MRAs had a significant asso-
ciation with the outcome in this analysis. However,
beta‐blockers were not significantly associated, which is con-
trary to what would have been expected based on prior
knowledge.8 We do not have a clear explanation for this phe-
nomenon and hypothesize that it could be related to catego-
rization of MPR, which leads to a loss of data and power.
Moreover, women had a lower prescription rate of disease‐
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modifying drugs. However, adherence to medication and im-
pact of adherence on outcome was not different between
sexes. This could be in line with the work of Santema et al.
who showed that women with HFrEF need lower doses
(50% of recommended dose) of ACE‐I/ARB and beta‐blockers
than men.27 This emphasizes the need for a sufficiently
powered prospective cohort study for sex‐stratified analysis
on use, dosage, and adherence of common HF medication
on outcomes, also distinguishing for left ventricular ejection
fraction.
Strengths and limitations
Our study has several strengths. First, by using big data, a
more representative, epidemiological overview compared
with RCTs was given due to lower selection bias and a higher
percentage of women. The results are more generalizable
and apply to the CHF population at large in the Netherlands
and possibly the rest of the EU. Second, extensive pharmacy
data were available, and utilizing MPR with a cut‐off of 0.809
and prescribed daily dose, because daily defined dose is a
poor estimator,28 we reliably estimated medication adher-
ence. This is the first step towards mapping patient compli-
ance to medication. Last but not least, we compared our
findings to multiple, large national registries, like the
CHECK‐HF, to assess the validity of our findings. However,
several limitations of this study should also be acknowledged
using the checklist for retrospective database studies as a
reference.29
First of all, limitations specific to study design are that
data wrangling is more difficult due to complex data with
an incomplete view. The lack of detailed medical data, such
as HF aetiology, left ventricular ejection fraction, New York
Health Association class, smoking status, body mass index,
and laboratory values, complicates inferences on the
results.29 Second, despite extensive adjustment for con-
founders in multivariable analysis, other (clinically) relevant
confounders are lacking and residual confounding may be
an issue. Regarding co‐morbidity selection, using the DRG/
FKG method, a reasonable overview can be given. How-
ever, in most cases, the number of patients is susceptible
to variation in criteria for diagnosis, and FKG data are
prone to bias ‘healthier patients’. In our study, hyperten-
sive disease, hypercholesterolaemia, and ischaemic heart
disease showed to be protective of the outcome due to
this reason. Therefore, caution is advised when interpreting
these results. Third, due to the nature of data collection on
insurance claims and the inherent delay that comes with it,
not all data on hospitalisations might be present, leading to
an incorrect representation. Furthermore, in HIC databases,
coding can be subject to incorrect labelling (dyspnoea could
be listed under CHF or COPD code), which can affect the
validity of the results. This is however estimated at a max-
imum of 5%. Changes over time in codes can also lead to
unreliable data,29 but quality check did not reveal any rele-
vant changes that could affect the study findings.
Conclusions
In a large, representative sample of the Dutch population,
as captured in a HIC database, men with CHF had a 25%
higher incidence of death or HF admission than women.
The influence of co‐morbidities on the studied outcome
was higher in women than in men, in particular for RI,
COPD/asthma, and diabetes. No difference in sex for med-
ication adherence and adherence in relation to the out-
come was observed. These results underscore the merit
of HIC databases as an addition to RCT data and demon-
strate that additional research into sex differences in HF
is warranted. To this end, the use and value of HIC data-
bases should be further evaluated. Furthermore, treatment
of HF should move towards a more patient‐tailored ap-
proach by sub‐classifying patients based on co‐morbidities
and setting specific goals for these conditions that could
potentially complicate HF treatment. More research is
needed to determine these goals in (older) HF patients with
multi‐morbidity and polypharmacy.
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